An interventional study of Probiotic in Small Intestinal Bacterial Overgrowth and SIBO, sponsored by Nimble Science Ltd.. Active, not recruiting at 1 site in Canada. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-09-30.
Sponsored by Nimble Science Ltd. · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The goal of this study is to test the effect of a probiotic formulation on gastrointestinal symptoms, gut and small intestine microbiota in participants suffering from small intestinal bacterial overgrowth (SIBO). Two doses of probiotic will be evaluated against placebo.
The goal of this double-blinded, randomized, placebo-controlled clinical study is to evaluate whether two different doses of a probiotic formulation may have effect on gastrointestinal symptoms, as well as gut and small intestine microbiota, in participats suffering from SIBO. The two probiotic doses will be compared to a placebo.
The main research questions to be answered by this study are related to:
The study will include a 2 month intervention with the investigational products and assessments will be conducted at baseline, mid-intervention, end-of-intervention, and follow-up period, with the exception of SIBO diagnosis, which will be conducted at baseline and at follow-up.
121 studies on the registry are indexed under Dilatation, Pathologic; 19 are open to participants now.
This study's planned enrollment of 105 is above the median of 82 across 84 interventional studies indexed under Dilatation, Pathologic.
Browse Dilatation, Pathologic studies →Nimble Science Ltd. is the lead sponsor of 8 studies on the registry; 1 is open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Use of any medications in the week prior to the screening study visit, unless part of regular treatment, that could substantially alter gastrointestinal motor function (e.g., opioids, anticholinergics, or GLP-1 analogues); laxative use is allowed if used less than 3 times a week and it is willing to keep unchanged in the week prior to the SIMBA capsule ingestions. Proton pump inhibitors (PPIs) are allowed provided a of 48 hours is respected before swallowing the SIMBA capsules and PPI treatment is resumed only 4 hours thereafter.
o Prokinetic use. Potential participants who are not using prokinetics to treat SIBO may be eligible after a 2-week washout period, and willing to not use prokinetics for the study duration.
Participants over the age of 50 or older who have not had:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Washout period
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A high dosage probiotic per capsule
Dietary Supplement: Probiotic
A low dosage probiotic per capsule
Dietary Supplement: Probiotic
No probiotic dosage
The intervention consists of a probiotic either with a low or high dosage
Change in bloating/distension severity
The primary outcome will assess the changes in weekly median severity of bloating/distension, defined as pressure, fullness or sensation of increased girth with a daily assessment with an ordinal scale between probiotic groups and placebo.
Time frame: From baseline to end of intervention (week 8).
Median bloating-free days
Median bloating-free days per week at each intervention week and follow up
Time frame: Each intervention week and follow up (week 12) compared to baseline.
Change in median bloating/distension severity
Change in median bloating/distension severity assessed by an ordinal scale (0 no severity- 10 extreme severity) at all intervention weeks (with the exception of end-of-intervention, as described in the primary outcome)
Time frame: At all intervention weeks (with the exception of end-of-intervention, as described in the primary outcome) and follow-up (week 12) compared to baseline.
Change in abdominal discomfort/pain
Change in abdominal discomfort/pain assessed by an ordinal scale (0 no pain - 10 extreme pain)
Time frame: At mid-intervention (week 4), end of intervention (week 8), and follow-up (week 12) compared to baseline
Changes in gastrointestinal symptoms
Changes in gastrointestinal symptoms assessed with GSRS
Time frame: At mid-intervention (week 4), end of intervention (week 8), and follow-up (week 12) compared to baseline.
Changes in stool frequency and consistency
Changes in stool frequency and consistency assessed with the Bristol Stool Scale (scoring 1 watery - 7 hard)
Time frame: At mid-intervention (week 4), end of intervention (week 8), and follow-up (week 12) compared to baseline.
Changes in the quality of life
Changes in the quality of life assessed with the Short Form (SF)-36 questionnaire
Time frame: At mid-intervention (week 4), end of intervention (week 8), and follow-up (week 12) compared to baseline.
Changes in reflux incidence and severity
Changes in reflux incidence and severity assessed with the modified reflux symptoms (mRESQ)
Time frame: At mid-intervention (week 4), end of intervention (week 8), and follow-up (week 12) compared to baseline.
Changes in the severity of IBS symptoms
Changes in the severity of IBS symptoms assessed with IBS Severity Scoring System (IBS-SSS) questionnaire
Time frame: At mid-intervention (week 4), end of intervention (week 8), and follow-up (week 12) compared to baseline.
Recovery rate of the probiotic strain
Recovery rate of the probiotic strain in small intestine and stool specimens
Time frame: At mid-intervention (week 4) end of intervention (week 8), and follow-up (week 12) compared to baseline.
Microbiome changes within small intestine, fecal and saliva samples
Changes in the the bacterial populations with the small intestine, fecal and saliva microbiomes represented as a diversity ratio
Time frame: At mid-intervention (week 4), end of intervention (week 8), and follow-up (week 12) compared to baseline.
Investigation how the microbiome and SIBO associate with each other though bacterial population analyses.
Exploring the correlation of select bacterial populations with SIBO through analysis of the small intestine and fecal microbiomes using metagenomics methodologies.
Time frame: Through study completion, an average of 1 year
Change in SIBO positivity rate
Change in SIBO positivity rate assessed by glucose breath test
Time frame: Through study completion, an average of 1 year
Exploratory metabolomic analysis
To investigate whether certain metabolites present in the small intestine, fecal, saliva samples may be associated with the presence/absence of SIBO. Using untargeted metabolomic methodologies.
Time frame: Through study completion, an average of 1 year
Exploratory: Quantifying the probiotic cell proportions
Determine the proportion of probiotic cells in spore versus germinated form using qPCR methodologies
Time frame: Through study completion, an average of 1 year
Safety outcomes
To collect safety data on the probiotic formulation and the SIMBA capsule by monitoring adverse events throughout the study.
Time frame: Through study completion, an average of 1 year
Plan to share: No — Select data with be shared with the participants
No publications or documents are linked to this record.
Started Jul 2024 (actual). Primary completion is estimated for Apr 2027, 33 months after the start.
Of 27 interventional studies with no phase under Dilatation, Pathologic, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 37. This study's planned 33 months is above that.
Since we started tracking on Sep 25, 2026, the dates moved once, on Sep 30, 2026: primary completion Dec 2026 → Apr 2027 and completion Dec 2026 → Sep 2027.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Probiotic
Nimble Science Ltd.